Abstract: A method of producing a composition in powder form involves the following steps (a) to (c): (a) providing highly dispersed silica particles, hydrophobic silica particles, and a cationic surfactant; (b) forming primary hydrophobic silica particles carrying the cationic surfactant on their surface and/or agglomerates of these primary particles; and (c) mixing the highly dispersed silica particles with the product obtained in step (b), thereby obtaining the composition in powder form; and a composition in powder form obtainable by the method.

Abstract: The disclosure relates to a safeguarding module, a method, and a system for safeguarding an apparatus in the medical environment against an unauthorised operation of the apparatus, wherein the authorisation is dependent upon a linking event between two linking partners within the framework of an operation of the apparatus, wherein the apparatuses are connected via a network, and wherein one of the linking partners is an item which is used during the operation of the apparatus. The system comprises a plurality of apparatuses, wherein in each case an apparatus comprises a safeguarding module, comprising: a read-in interface for reading-in a first identifier and a second identifier; a processing unit which is designed to perform the safeguarding method; a memory for storing the calculated documentation value in a distributed ledger structure; and an interface to the network, via which the apparatuses exchange data.

Abstract: The present disclosure provides crystalline solid forms, spray-dried dispersions and pharmaceutical compositions, including solid oral dosage forms, of (S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-phenylpropan-1-one (“Compound 1”), and preparation methods thereof.

Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

Abstract: The disclosure provides novel chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).

Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

Abstract: A home dialysis machine network is provided that includes a home dialysis machine and one or more walk-up service centers. The walk-up service center can be equipped with a diagnostic tool, parts, or supplies for the home dialysis machine. Methods of maintaining a home dialysis machine are also provided as are service centers equipped with a transportation service or office, a diagnostics department, an education and training department, a consultation department, an exercise and spa department, an entertainment department, a sales department, a repair shop, a new technologies department, a pharmacy, and a doctor's office.

Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

Abstract: Contactless operation of a device is provided via a mobile pointing apparatus and a receiving arrangement associated with the device. The mobile pointing apparatus includes a signal emitter for emitting an optical or electromagnetic signal, and the receiving arrangement associated with the device determines a pointing target of the mobile pointing apparatus relative to the device based on the signal emitted by the mobile pointing apparatus and triggers a function of the device based on the pointing target of the mobile pointing apparatus.

Abstract: A home dialysis machine network is provided that includes a home dialysis machine and one or more walk-up service centers. The walk-up service center can be equipped with a diagnostic tool, parts, or supplies for the home dialysis machine. Methods of maintaining a home dialysis machine are also provided as are service centers equipped with a transportation service or office, a diagnostics department, an education and training department, a consultation department, an exercise and spa department, an entertainment department, a sales department, a repair shop, a new technologies department, a pharmacy, and a doctor's office.

Abstract: The invention relates to a communications device for non-electric communication between fluidically interconnected devices, the communications device being designed to be mounted in a position in a fluidic overall system formed by the fluidically interconnected devices and to receive and/or emit non-electric signals, in particular in the form of pressure or sound signals, the non-electric signals being transmitted via a line that fluidically interconnects the devices. The invention further relates to a method for non-electric communication between fluidically interconnected devices, the non-electric communication taking place preferably by means of pressure and/or sound signals via at least one line that fluidically interconnects the devices.

Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.

Abstract: The disclosure relates to a pharmaceutical or dietary composition in the form of a soft gel capsule comprising a liquid or semisolid fill and a shell, the fill comprising at least one active ingredient or dietary supplement, dissolved, suspended or solubilized in a solution comprising water and alcohol, and a solubilizer and thickening agent. The disclosure furthermore relates to methods of reducing brittleness and fragility of such soft gel capsules.

Abstract: The present teachings generally include parabiotic dialysis systems and techniques. For example, the present disclosure includes parabiotic liver dialysis, e.g., for use in settings with limited resources. To this end, a parabiotic liver dialysis system may include a device having a semipermeable membrane with an average pore size that allows for the passage of albumin therethrough. In such a system, a first extracorporeal circuit may connect the device to the vascular system of a first animal (e.g., a liver patient), and a second extracorporeal circuit may connect the device to the vascular system of a second animal (e.g., a human with normal liver function), where the exchange of albumin therebetween is facilitated through the device. The present disclosure also includes various safety measures for parabiotic dialysis systems and techniques, such as biometric verification systems and techniques.